Resources

End-to-End Optimization of CAR-T Manufacturing: Boosting Lentiviral Production and T-Cell Transduction with Viral Sensitizer Technology
May 10th, 2025PosterCell & Gene Therapies
Increasing AAV8 Yields in the iCELLis™ Nano Bioreactor Using VSE™ Technology
April 29th, 2025WhitepaperCell & Gene Therapies
High-Throughput Screening of Next Generation Small Molecule Enhancers and Process Automation in Cloud-Connected Bioreactors
April 20th, 2025PosterCell & Gene Therapies
Small Gains, Big Wins: How Incremental Yield Increases Drive Major Cost-Savings in Cell and Gene Therapy Manufacturing
April 20th, 2025ArticleCell & Gene Therapies
Harnessing the Statistical Power of Design of Experiments to Maximize Viral Vector Biomanufacturing Production
April 20th, 2025ArticleCell & Gene Therapies
Overcoming the Challenges of Antiviral Defenses in Viral Vector Manufacturing
April 20th, 2025ArticleCell & Gene Therapies
Pfizer Paper – Production of rAAV by plasmid transfection induces Antiviral inflammatory responses in suspension HEK293 cells
April 20th, 2025ArticleCell & Gene Therapies
The Impact of Antiviral Defenses in Viral Vector Production
April 20th, 2025WhitepaperCell & Gene Therapies, Vaccines
Increased AAV Yield: From Screen to Scale Up to Cost Savings Using Viral Sensitizers (VSE™) Technology
April 20th, 2025PosterCell & Gene Therapies
Viral Sensitizers Unleash Host Cell Potential to Enhance AAV Production
April 20th, 2025PosterCell & Gene Therapies

Virica uses cookies to provide a better website experience of our website. I agree to the Privacy Policy and Terms of Use. OK